-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 OAoALlblgz9V+S02TAnC+2UUFznfXTFT3DrTL0JRia3oDbIeQpOZPRBs7XxySBUH
 TqPyjqtls4bjN5OXhEHF4w==

<SEC-DOCUMENT>0000950134-07-021298.txt : 20071015
<SEC-HEADER>0000950134-07-021298.hdr.sgml : 20071015
<ACCEPTANCE-DATETIME>20071015153935
ACCESSION NUMBER:		0000950134-07-021298
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20071009
ITEM INFORMATION:		Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20071015
DATE AS OF CHANGE:		20071015

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IRIDEX CORP
		CENTRAL INDEX KEY:			0001006045
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		IRS NUMBER:				770210467
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1230

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-27598
		FILM NUMBER:		071171937

	BUSINESS ADDRESS:	
		STREET 1:		1212 TERRA BELLA AVE
		CITY:			MOUNTAIN VIEW
		STATE:			CA
		ZIP:			94043
		BUSINESS PHONE:		6509404700

	MAIL ADDRESS:	
		STREET 1:		1212 TERRA BELLA AVENUE
		CITY:			MOUNTAIN VIEW
		STATE:			CA
		ZIP:			94043
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f34602e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>






<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>Washington, DC 20549</B>
</DIV>
<DIV align="center">
<DIV style="width: 30%; margin-top: 6pt; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>
</DIV>
<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 or 15(d) of<BR>
The Securities Exchange Act of 1934</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Date of Report (Date of earliest event reported)
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>October&nbsp;9, 2007</B>
</DIV>
<DIV align="center">
<DIV style="width: 30%; margin-top: 6pt; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>
</DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>IRIDEX CORPORATION</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 2pt">(Exact name of registrant as specified in its charter)
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="center"><B>Delaware</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>0-27598</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>77-0210467</B></TD>
</TR>

<TR>
    <TD style="border-top: 1px solid black">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD style="border-top: 1px solid black">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD style="border-top: 1px solid black">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top">(State or other jurisdiction of <BR>
incorporation)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Commission File Number)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(IRS Employer <BR>
Identification No.)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>1212 Terra Bella Avenue<BR>
Mountain View, California 94043</B><BR>
(Address of principal executive offices, including zip code)
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>(650)&nbsp;940-4700</B><BR>
(Registrant&#146;s telephone number, including area code)
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">(Former name or former address, if changed since last report)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT>&nbsp;Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT>&nbsp;Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT>&nbsp;Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT>&nbsp;Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
</DIV>


<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<!-- TOC -->
<A name="toc"><DIV align="CENTER" style="page-break-before:always"><U><B>TABLE OF CONTENTS</B></U></DIV></A>

<P><CENTER>
<TABLE border="0" width="90%" cellpadding="0" cellspacing="0">
<TR>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="76%"></TD>
</TR>
<TR><TD></TD><TD colspan="8"><A HREF="#000">Item&nbsp;5.02.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#001">Item&nbsp;9.01.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.</A></TD></TR>
<TR><TD colspan="9"><A HREF="#002">SIGNATURES</A></TD></TR>
<TR><TD colspan="9"><A HREF="#003">EXHIBIT INDEX</A></TD></TR>
<TR><TD colspan="9"><A HREF="f34602exv99w1.htm">EXHIBIT 99.1</A></TD></TR>
</TABLE>
</CENTER>
<!-- /TOC -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>




<!-- link2 "Item&nbsp;5.02.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers" -->
<DIV align="left"><A NAME="000"></A></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;5.02.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Departure of Directors or Certain Officers; Election of Directors; Appointment of
Certain Officers; Compensatory Arrangements of Certain Officers</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(d)
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%"><I>Appointment of James B. Hawkins to Iridex&#146;s Board of Directors and the Audit and Corporate
Governance Committee</I>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">On October&nbsp;9, 2007, James B. Hawkins was appointed to the board of directors (the &#147;Board of
Directors&#148;) of IRIDEX Corporation, (the &#147;Company&#148;) pursuant to provisions of that certain
Securities Purchase Agreement (the &#147;Agreement&#148;), dated August&nbsp;31, 2007, by and between the Company
and the purchasers named therein (the &#147;Purchasers&#148; or &#147;BlueLine&#148;). Pursuant to the Agreement the
Company sold $5&nbsp;million of securities in the Company to BlueLine. In addition, BlueLine received
the right to designate two individuals for appointment to the Company&#146;s Board of Directors, one of
which is at BlueLine&#146;s discretion and the second of which is subject to the Company&#146;s reasonable
approval. Furthermore, subject to the fiduciary duties of the Board of Directors, for so long as
BlueLine holds any shares of Series&nbsp;A Preferred Stock issued pursuant to the Agreement, the Company
will continue to nominate such designees for reelection at each of the Company&#146;s annual or special
meetings at which election of directors to the Board of Directors is proposed for consideration by
the stockholders. Mr.&nbsp;Hawkins was the designee of BlueLine nominated subject to the Company&#146;s
reasonable approval under the Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In connection with Mr.&nbsp;Hawkins&#146;s election to the Board of Directors, the Company also approved the
grant of a non-qualified stock option for the purchase of 15,000 shares of common stock, which
grant will be effective as of October&nbsp;31, 2007, at an exercise price per share equal to the fair
market value on that date. Assuming continued service on the Board of Directors, such options vest
and become exercisable over 36&nbsp;months, with 1/36<SUP style="font-size: 85%; vertical-align: text-top">th </SUP> of the shares subject to
the option vesting each month following the grant date. In addition, Mr.&nbsp;Hawkins will automatically
receive a nonstatutory option to purchase 5,000 shares of common stock upon his annual reelection
to the Board of Directors by the stockholders, with 1/12<SUP style="font-size: 85%; vertical-align: text-top">th </SUP> of the shares
vesting each month. The options granted to Mr.&nbsp;Hawkins will be granted under the Company&#146;s 1998
Stock Plan and have a term of 7&nbsp;years unless terminated sooner upon the termination of Mr.
Hawkins&#146;s status as a director or otherwise pursuant to the 1998 Stock Plan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In April&nbsp;2004, Mr.&nbsp;Hawkins joined Natus Medical Incorporated where he currently serves as
President, Chief Executive Officer, and Director. Prior to joining Natus Medical, Mr.&nbsp;Hawkins was
President, Chief Executive Officer, and a Director of Invivo Corporation, a developer and
manufacturer of multi-parameter vital sign monitoring equipment, and its predecessor, from 1985
through January&nbsp;2004. Mr.&nbsp;Hawkins also served as Secretary of Invivo from 1986 until January&nbsp;2004.
He earned his undergraduate degree in Business Commerce from Santa Clara University and holds a
Masters of Business Administration degree from San Francisco State University.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">After the
Board of Directors determined that Mr.&nbsp;Hawkins was independent,
as defined under the listing standards of the Nasdaq Stock Market, the Board of Directors appointed Mr.&nbsp;Hawkins to the Audit and Corporate Governance Committee.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">A copy of the press release announcing Mr.&nbsp;Hawkins&#146;s appointment is attached hereto as Exhibit&nbsp;99.1
and is incorporated herein by reference.
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%"><I>Appointment of William M. Moore to the Compensation and Nominating Committee</I>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">As previously disclosed in the Company&#146;s Current Report on Form 8-K filed with the Securities
Exchange Commission on September&nbsp;12, 2007, on September&nbsp;6, 2007 William M. Moore was appointed to
serve on the Board of Directors. At such time the Board of Directors had not determined the
committees on which Mr.&nbsp;Moore would serve, however, on October&nbsp;9, 2007, the Board of Directors
appointed Mr.&nbsp;Moore to the Compensation and Nominating Committee.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<!-- link2 "Item&nbsp;9.01.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits." -->
<DIV align="left"><A NAME="001"></A></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;9.01.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Financial Statements and Exhibits.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exhibits</U>.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="16%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="79%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left">Exhibit</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><U>Number</U></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left"><U>Description</U></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press release dated October&nbsp;15, 2007.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<!-- link1 "SIGNATURES" -->
<DIV align="left"><A NAME="002"></A></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SIGNATURES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>IRIDEX CORPORATION</B> <BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>

<TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/
Barry G. Caldwell&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><B>Name:&nbsp;&nbsp;</B></TD>
    <TD colspan="1" style="border-bottom: 1px solid #000000" align="left">Barry G. Caldwell&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><B>Title:&nbsp;&nbsp;</B></TD>

<TD colspan="1" style="border-bottom: 1px solid #000000" align="left">President
and Chief Executive Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Date: October&nbsp;15, 2007
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<!-- link1 "EXHIBIT INDEX" -->
<DIV align="left"><A NAME="003"></A></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>EXHIBIT INDEX</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="16%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="79%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left">Exhibit</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><U>Number</U></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left"><U>Description</U></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press release dated October&nbsp;15, 2007.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>f34602exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv99w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;99.1</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="53%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>FOR IMMEDIATE RELEASE</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Contact:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Larry Tannenbaum</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Chief Business Officer</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(650) 940-4700</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">October&nbsp;15, 2007<BR>
Mountain View, California

</DIV>

<DIV align="center" style="font-size: 12pt; margin-top: 18pt"><B>James B. Hawkins Appointed to IRIDEX Board of Directors</B>
</DIV>

<DIV align="center" style="font-size: 10pt"><I>Natus Medical CEO Brings More Than 20 Years of Public Company Experience</I></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">IRIDEX Corporation (NASDAQ: IRIX) announced today the appointment of James B. Hawkins, president
and CEO of Natus Medical, Inc. (NASDAQ: BABY) to its Board of Directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;We are excited that Jim Hawkins has decided to become a part of the IRIDEX organization,&#148; said
Theodore A. Boutacoff, chairman of the board at IRIDEX. &#147;Jim brings to our Board more than 20
years of experience as a public company CEO, including 14&nbsp;years in medical devices. We believe his
medical device industry and operational experience will be highly valuable to IRIDEX. Throughout
his career, Jim has executed strategic acquisitions, international expansion and other corporate
initiatives designed to drive revenue and earnings growth. We look forward to his contributions.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Mr.&nbsp;Hawkins is currently the president, CEO and a director of Natus Medical, Inc., a developer,
manufacturer and marketer of products for the detection, monitoring, treatment and tracking of
common medical disorders in newborns. During his tenure at Natus, he has executed a growth
strategy that focuses on sales force realignment, dramatic reductions in overhead expenses and
revenue growth, which has resulted in a significant increase in operating margins, revenue and
market capitalization. He has also initiated and negotiated numerous acquisitions which have been
immediately accretive to earnings.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;I am pleased with the opportunity to join the Board of Directors of IRIDEX,&#148; said Mr.&nbsp;Hawkins.
&#147;IRIDEX has a solid portfolio of products, recently enhanced by the acquisition of the Laserscope
aesthetics business, which has positioned them to achieve long-term, profitable growth. I look
forward to working with the company and contributing to their progress.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Prior to Natus, Mr.&nbsp;Hawkins spent nearly 20&nbsp;years as the president, CEO and a director of Invivo
Corporation, a developer, manufacturer and marketer of multi-parameter vital sign monitoring
equipment used in hospitals. Invivo was acquired by Intermagnetics General Corporation in 2004 at
a 45% premium to its share price. Mr.&nbsp;Hawkins began his professional career by founding Corporate
Financial Consulting Company, a specialized consultancy firm focused on assisting start-up and
early-stage companies with all aspects
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">of financial management and control. He earned a Bachelor of Commerce degree from Santa Clara
University and an MBA from San Francisco State University.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>About IRIDEX</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">IRIDEX Corporation is a leading worldwide provider of therapeutic based laser systems, disposable
laser probes and delivery devices to treat eye diseases in ophthalmology and skin disorders in the
aesthetics market. IRIDEX products are sold in the United States through a direct sales force and
internationally through a combination of a direct sales force and a network of approximately 97
independent distributors into 107 countries.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Safe Harbor</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This announcement contains forward-looking statements within the meaning of Section&nbsp;27A of the
Securities Act of 1933, as amended and Section&nbsp;21E of the Securities Act of 1934, as amended,
relating to the company&#146;s future growth and its ability to return to profitability. Actual results
could differ materially and adversely from those projected in the forward-looking statements based
on, among other things, the company&#146;s ability to effectively integrate the aesthetics business
acquired from Laserscope and to realize efficiencies and synergies relating thereto, and the
results of the company&#146;s ongoing business, including order and shipment rates for the company&#146;s
ophthalmology and dermatology product lines, the rate of sales to OEM customers, the rate of growth
in sales of disposables and services, the rate of introduction and market acceptance of the
company&#146;s products, and the impact of any continuing weakness and uncertainties related to general
economic conditions or weakness in overall demand in the company&#146;s markets, especially with regard
to the company&#146;s dermatology products which are typically used for elective procedures that can be
deferred. Please see a detailed description of these risks and other risks that the company is
subject to contained in our Quarterly Reports on Form 10-Q and Annual Report on Form 10-K for the
fiscal year ended December&nbsp;30, 2006 filed with the Securities and Exchange Commission. Forward-
looking statements contained in this announcement are made as of this date and will not be updated.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
